Prosecution Insights
Last updated: November 18, 2026
Application No. 18/566,672

USE OF MANGOSTEEN FRUIT SHELL EXTRACT IN THE PREPARATION OF A MEDICAMENT FOR TREATING PSORIASIS

Non-Final OA §102§103
Filed
Dec 04, 2023
Priority
Nov 05, 2021 — nonprovisional of PCTCN2021128869
Examiner
MELLER, MICHAEL V
Art Unit
1655
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Xantho Biotechnology Co. Ltd.
OA Round
3 (Non-Final)
47%
Grant Probability
Moderate
3-4
OA Rounds
76%
With Interview

Examiner Intelligence

Grants 47% of resolved cases
47%
Career Allowance Rate
363 granted / 768 resolved
-12.7% vs TC avg
Strong +29% interview lift
Without
With
+28.6%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
56 currently pending
Career history
830
Total Applications
across all art units

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-5, 7, 11 are rejected under 35 U.S.C. 102 (a) (1) as being anticipated by WO 21017016428. WO teaches a use of a composition in preparation of a medicament for treating skin diseases, wherein the composition comprises an effective amount of extract of mangosteen rind, the extract of mangosteen rind is a water extract and/or an alcohol extract of mangosteen rind, the mangosteen rind is the outer rind and/or the inner rind of the mangosteen rind, the extract of mangosteen rind comprises α-mangostin and γ-mangostin, the composition is a parenteral preparation, the parenteral preparation is an external preparation, the skin diseases include, but are not limited to, psoriasis, psoriatic lesions, see claims 1-5, 8-10, description, paragraph 29. Applicant argues that allegedly 1-8 % of the mangosteen fruit extract is not administered in WO. This is simply not the case or in the very least it would have been obvious to use such an amount since clearly WO does in fact use 20 mg/kg to 200 mg/kg and it is noted on page 9 that 0.5 % to 5% mangosteen creams are used. The animal test in Example 2 of WO clearly indicates that 1 time/1 day was administered for a week. Therefore, all of the limitations of the claims are indeed taught by WO. Applicant alleges that “the relevant part” of a reference entitled “CBC Biotechnological & Pharmaceutical Co., Ltd., KARAC CREAM, Health Department Pharmaceutical Production License No. 049670 Certificate Information, September 18, 2018-September 18, 2028” in Applicant’s IDS is submitted but the entire disclosure needs to be properly translated into English. In any event, applicant argues that this allegedly shows that much more than 5-7 days is needed to achieve beneficial results but this is clearly not the case since WO teaches 7 days (one week) as noted above. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1-5, 7, 10 and 11 are rejected under 35 U.S.C. 103 as being unpatentable over WO 21017016428. WO teaches a use of a composition in preparation of a medicament for treating skin diseases, wherein the composition comprises an effective amount of extract of mangosteen rind, the extract of mangosteen rind is a water extract and/or an alcohol extract of mangosteen rind, the mangosteen rind is the outer rind and/or the inner rind of the mangosteen rind, the extract of mangosteen rind comprises α-mangostin and γ-mangostin, the composition is a parenteral preparation, the parenteral preparation is an external preparation, the skin diseases include, but are not limited to, psoriasis, psoriatic lesions, see claims 1-5, 8-10, description, paragraph 29. MPEP 2144.05, subsection II. II. ROUTINE OPTIMIZATION A. Optimization Within Prior Art Conditions or Through Routine Experimentation Generally, differences in concentration or temperature will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955) (Claimed process which was performed at a temperature between 40°C and 80°C and an acid concentration between 25% and 70% was held to be prima facie obvious over a reference process which differed from the claims only in that the reference process was performed at a temperature of 100°C and an acid concentration of 10%.); see also Peterson, 315 F.3d at 1330, 65 USPQ2d at 1382 ("The normal desire of scientists or artisans to improve upon what is already generally known provides the motivation to determine where in a disclosed set of percentage ranges is the optimum combination of percentages."); In re Hoeschele, 406 F.2d 1403, 160 USPQ 809 (CCPA 1969) (Claimed elastomeric polyurethanes which fell within the broad scope of the references were held to be unpatentable thereover because, among other reasons, there was no evidence of the criticality of the claimed ranges of molecular weight or molar proportions.). For more recent cases applying this principle, see Merck & Co. Inc. v. Biocraft Lab. Inc., 874 F.2d 804, 10 USPQ2d 1843 (Fed. Cir.), cert. denied, 493 U.S. 975 (1989); In re Kulling, 897 F.2d 1147, 14 USPQ2d 1056 (Fed. Cir. 1990); and In re Geisler, 116 F.3d 1465, 43 USPQ2d 1362 (Fed. Cir. 1997); Smith v. Nichols, 88 U.S. 112, 118-19 (1874) (a change in form, proportions, or degree "will not sustain a patent"); In re Williams, 36 F.2d 436, 438 (CCPA 1929) ("It is a settled principle of law that a mere carrying forward of an original patented conception involving only change of form, proportions, or degree, or the substitution of equivalents doing the same thing as the original invention, by substantially the same means, is not such an invention as will sustain a patent, even though the changes of the kind may produce better results than prior inventions."). See also KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398, 416 (2007) (identifying "the need for caution in granting a patent based on the combination of elements found in the prior art."). B. There Must Be an Articulated Rationale Supporting the Rejection In order to properly support a rejection on the basis that an invention is the result of "routine optimization", the examiner must make findings of relevant facts, and present the underpinning reasoning in sufficient detail. The articulated rationale must include an explanation of why it would have been routine optimization to arrive at the claimed invention and why a person of ordinary skill in the art would have had a reasonable expectation of success to formulate the claimed range. See In re Stepan, 868 F.3d 1342, 1346, 123 USPQ2d 1838, 1841 (Fed. Cir. 2017). See also In re Van Os, 844 F.3d 1359,1361,121 USPQ2d 1209, 1211 (Fed. Cir. 2017 ("Absent some articulated rationale, a finding that a combination of prior art would have been ‘common sense’ or ‘intuitive’ is no different than merely stating the combination ‘would have been obvious.’"); Arendi S.A.R.L. v. Apple Inc., 832 F.3d 1355, 1362, 119 USPQ2d 1822 (Fed. Cir. 2016) ("[R]eferences to ‘common sense’ … cannot be used as a wholesale substitute for reasoned analysis and evidentiary support … ."). The Supreme Court has clarified that an "obvious to try" line of reasoning may properly support an obviousness rejection. In In re Antonie, 559 F.2d 618, 195 USPQ 6 (CCPA 1977), the CCPA held that a particular parameter must first be recognized as a result-effective variable, i.e., a variable which achieves a recognized result, before the determination of the optimum or workable ranges of said variable might be characterized as routine experimentation, because "obvious to try" is not a valid rationale for an obviousness finding. However, in KSR International Co. v. Teleflex Inc., 550 U.S. 398 (2007), the Supreme Court held that "obvious to try" was a valid rationale for an obviousness finding, for example, when there is a "design need" or "market demand" and there are a "finite number" of solutions. 550 U.S. at 421 ("The same constricted analysis led the Court of Appeals to conclude, in error, that a patent claim cannot be proved obvious merely by showing that the combination of elements was ‘[o]bvious to try.’ ... When there is a design need or market pressure to solve a problem and there are a finite number of identified, predictable solutions, a person of ordinary skill has good reason to pursue the known options within his or her technical grasp. If this leads to the anticipated success, it is likely the product not of innovation but of ordinary skill and common sense. In that instance the fact that a combination was obvious to try might show that it was obvious under §103."). Thus, after KSR, the presence of a known result-effective variable would be one, but not the only, motivation for a person of ordinary skill in the art to experiment to reach another workable product or process. The amount of mangosteen fruit shell extract is clearly a result effective variable, thus making it obvious to use 1%-5 % of the mangosteen fruit shell extract especially when WO teaches that the effective dose of the mangosteen is from 20 mg/kg to 200 mg/kg clearly giving support and motivation to use at such low amounts. Applicant argues that allegedly 1-8 % of the mangosteen fruit extract is not administered in WO. This is simply not the case or in the very least it would have been obvious for one having ordinary skill in the art to use such an amount since clearly WO does in fact use 20 mg/kg to 200 mg/kg and it is noted on page 9 that 0.5 % to 5% mangosteen creams are used. The animal test in Example 2 of WO clearly indicates that 1 time/1 day was administered for a week. Therefore, all of the limitations of the claims are indeed taught by WO. Applicant alleges that “the relevant part” of a reference entitled “CBC Biotechnological & Pharmaceutical Co., Ltd., KARAC CREAM, Health Department Pharmaceutical Production License No. 049670 Certificate Information, September 18, 2018-September 18, 2028” in Applicant’s IDS is submitted but the entire disclosure needs to be properly translated into English. In any event, applicant argues that this allegedly shows that much more than 5-7 days is needed to achieve beneficial results but this is clearly not the case since WO teaches 7 days (one week) as noted above. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICHAEL V MELLER whose telephone number is (571)272-0967. The examiner can normally be reached M-F 9 am-5:30 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anand Desai can be reached at 571-272-0947. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. MICHAEL V. MELLER Primary Examiner Art Unit 1655 /MICHAEL V MELLER/Primary Examiner, Art Unit 1655
Read full office action

Prosecution Timeline

Show 3 earlier events
Feb 13, 2026
Response Filed
May 19, 2026
Final Rejection mailed — §102, §103
Aug 20, 2026
Request for Continued Examination
Aug 24, 2026
Response after Non-Final Action
Sep 14, 2026
Non-Final Rejection mailed — §102, §103
Nov 11, 2026
Interview Requested
Nov 12, 2026
Interview Requested
Nov 17, 2026
Interview Requested

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12797426
Cannabinoid Concentration Process
5y 6m to grant Granted Nov 17, 2026
Patent 12788766
CANNABIDIOL-TYPE CANNABINOID COMPOUND
5y 5m to grant Granted Nov 10, 2026
Patent 12778882
COMPOSITIONS AND METHODS FOR TREATING OCULAR DISORDERS
4y 2m to grant Granted Nov 03, 2026
Patent 12766225
METHOD FOR PREPARING AN ALLOGRAFT OR XENOGRAFT MATERIAL FROM A CRYSTALLINE LENS CAPSULE
4y 9m to grant Granted Oct 20, 2026
Patent 12766168
FECAL MATTER FOR TREATMENT OF CACHEXIA
3y 11m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
47%
Grant Probability
76%
With Interview (+28.6%)
High
PTA Risk
Based on 768 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month